A senior pharmaceutical executive collapsed during an Oval Office event where former U.S. President Donald Trump was announcing a new initiative to reduce the prices of obesity drugs. The incident caused a sudden interruption to the live broadcast of the announcement, which was centered on a major agreement between the Trump administration and leading pharmaceutical manufacturers.
According to eyewitnesses, the executive, later identified as Gordon Findlay of Novo Nordisk, lost his balance and fell shortly after Trump unveiled details of a partnership with drugmakers Eli Lilly and Novo Nordisk. The agreement aims to dramatically cut the cost of GLP-1 medications, including the widely prescribed weight-loss drugs Wegovy and Zepbound. These drugs, which have gained immense popularity for their effectiveness in treating obesity and diabetes, have been criticized for their high retail prices, often reaching several hundred dollars a month.
The incident occurred just minutes into Trump’s remarks from behind the Resolute Desk, where he introduced the new “Most Favored Nations” drug pricing policy. Witnesses said Dr. Mehmet Oz, who currently heads the Centers for Medicare & Medicaid Services, quickly moved forward to assist Findlay, preventing further injury. Onlookers reported that the atmosphere in the room shifted immediately as Secret Service agents and White House medical personnel rushed to the scene. “The room went completely silent. Everyone froze for a moment,” said one attendee. “President Trump appeared visibly concerned and paused the proceedings until medics confirmed the man was responsive.”
White House Press Secretary Karoline Leavitt issued a brief statement shortly after the incident, clarifying that the executive had fainted but was in stable condition. “During the Most Favored Nations Oval Office announcement, a representative from one of the participating companies experienced a brief medical episode,” she said. “The White House Medical Unit responded swiftly, and the gentleman is now doing well. The press event will resume shortly.”
The announcement was part of a larger effort to highlight the administration’s plan to make life-saving medications more accessible to the public. Under the new initiative, manufacturers of GLP-1 drugs will be allowed to sell directly to consumers through a forthcoming federal platform named TrumpRx. The service, which is expected to launch next year, will enable consumers to purchase oral versions of these drugs for as low as $149 per month, pending regulatory approval from the Food and Drug Administration (FDA).
President Trump described the deal as a “historic breakthrough” for American healthcare, saying it would help millions struggling with obesity and related conditions afford effective treatment. “For too long, Americans have paid the highest prices in the world for the same drugs,” Trump said during his address. “Today, we’re changing that. This partnership will make powerful new medications available at a fraction of the current cost.”
Eli Lilly and Novo Nordisk, the pharmaceutical giants behind these GLP-1 treatments, have both faced public pressure to lower prices amid skyrocketing demand. Industry analysts say the agreement marks one of the most aggressive moves yet to rein in drug costs, a longstanding issue in U.S. healthcare policy.
Following the brief interruption, the event resumed with the signing of a memorandum of understanding between the government and the companies involved. Officials indicated that the pricing model would serve as a template for future negotiations on other high-cost medications, including insulin and cancer drugs.
The executive who fainted, Gordon Findlay, was later seen walking out of the Oval Office with assistance from medical personnel. Sources confirmed that he did not require hospitalization and was recovering. The White House concluded the event with a renewed commitment to ensuring affordable access to essential drugs, emphasizing that the new plan could reshape pharmaceutical pricing in the United States.
The incident, though momentary, drew attention to the intensity and high stakes surrounding national healthcare reform discussions. It underscored both the urgency of the issue and the immense pressure on executives and policymakers seeking to balance innovation, affordability, and access in an industry at the center of public health debates.
